Day: March 31, 2026

VANCOUVER, British Columbia, March 31, 2026 (GLOBE NEWSWIRE) — SAGA Metals Corp. (“SAGA” or the “Company”) (TSXV: SAGA) (OTCQB: SAGMF) (FSE: 20H), a North American exploration company focused on critical mineral discoveries, is pleased to report additional assay results from drill holes R-0021, -0022 and -0023 completed in 2026 as part of its ongoing maiden Mineral Resource Estimate (“MRE”) diamond drill program at the Trapper Zone within the 100%-owned Radar Titanium-Vanadium-Iron Project near Cartwright, Labrador, Canada. Trapper South Assay HighlightsAnalytical results received for three (3) additional diamond drill holes (R-0021 to R-0023) from the MRE drill program reinitiated in 2026, delivering consistent broad intercepts of oxide mineralization. Key intercepts include:Hole R-0021:...

JENA, Germany, March 31, 2026 (GLOBE NEWSWIRE) — InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced it will participate in the Raymond James 2026 Biotech Innovation Symposium. Details are as follows: Raymond James 2026 Biotech Innovation SymposiumApril 14, 2026, in New York, NYThe Company will hold one-on-one investor meetings. About InflaRxInflaRx (Nasdaq: IFRX) is a biopharmaceutical company pioneering anti-inflammatory therapeutics by applying its proprietary anti-C5a and anti-C5aR technologies to discover, develop and commercialize highly potent and specific inhibitors of the complement activation factor C5a and its receptor, C5aR. C5a is a powerful inflammatory mediator involved in the progression of a wide variety of inflammatory...

VANCOUVER, British Columbia , March 31, 2026 (GLOBE NEWSWIRE) — Rio Silver Inc. (the “Company” or “Rio Silver”) (TSX.V: RYO) (OTC: RYOOF) is pleased to announce that it has closed its non-brokered private placement (the “Offering”), previously announced on February 25, 2026, by issuing an aggregate of 8,571,429 units (the “Units”) of the Company at a price of $0.35 per Unit for gross proceeds of $3,000,000. Each Unit is comprised of one common share of the Company and one-half of a common share purchase warrant (each whole warrant, a “Warrant”), with each Warrant exercisable to purchase an additional common share of the Company at a price of $0.50 per common share for a period of 24 months from the date of issue, subject to early expiry in the event that the closing price of the common...

NEWPORT BEACH, Calif., March 31, 2026 (GLOBE NEWSWIRE) — AGA Precision Systems LLC (“AGA”), a precision aerospace manufacturing company and wholly owned subsidiary of PMGC Holdings Inc. (NASDAQ: ELAB), today announced the execution of a Long-Term agreement (“LTA”) with Turbo-Jet Products Co., Inc. (“Turbo-Jet Products”), a California-based aerospace and defense supplier. Under the terms of the LTA, AGA will supply mission-critical aerospace and defense components in support of Turbo-Jet Products’ commercial and defense programs. The LTA provides an agreement framework that governs all future purchase orders issued during the LTA’s term. The LTA includes an initial five-year term, with provisions for annual renewals, supporting a long-term strategic supply relationship between the parties. Strategic Importance The company believes...

4basebio PLC (“4basebio” or the “Company”) Cambridge, UK, 31 March 2026 – 4basebio PLC (AIM: 4BB), a specialist in synthetic DNA manufacturing and nucleic acids for next-generation therapeutics, announces a significant expansion into a new innovation hub and manufacturing facility in Cambridge, UK, supporting growing demand for research and high-quality grade manufacturing of synthetic DNA for gene and cell therapies, mRNA vaccines, genome editing, or DNA vaccines. 31-35 Saxon Way, Bar Hill, is being leased from Peterhouse, the University of Cambridge’s oldest college, who have a long tradition of supporting academic excellence and scientific innovation. 4basebio is expected to move into the facility late summer 2026, once the building has been developed. The new facility will provide approximately 26,500 square...

Record Revenue, Net Income and Cash Flow from Operations MONTREAL, March 31, 2026 (GLOBE NEWSWIRE) — Aya Gold & Silver Inc. (TSX: AYA; OTCQX: AYASF) (“Aya” or the “Corporation”) today announced its financial and operational results for the fourth quarter and full year ended December 31, 2025. All amounts are in U.S. dollars unless otherwise noted. Full Year and Q4 2025 Highlights Financial HighlightsFull-year revenue of $202M in 2025, up five-fold, year-over-year (“YoY”), on 4.9 million silver equivalent ounces (“Moz AgEq”) sold, (up 223%), at a higher average net realized AgEq price of $41.61/oz (up 60%). Q4-2025 revenue of $75M, up 39% quarter-over-quarter (“QoQ”), driven by a higher average net realized AgEq price of $58.39/oz (up 47% QoQ and 111% YoY), as well as initial sales of the...

SUNNYVALE, Calif., March 31, 2026 (GLOBE NEWSWIRE) — On March 31, 2026, Seyond (02665.HK) announced its audited full-year results for 2025. During the reporting period, the company’s annual lidar shipments exceeded 332,000 units, representing a year-on-year increase of 45.0%. Along with the rapid expansion of business scale, operational quality also improved significantly: gross profit turned positive from a loss in 2024, with the gross profit margin rising to 7.9%. This milestone marks that, driven by economies of scale, cost optimization, and product structure upgrading, Seyond has entered a new phase of high-quality growth.Continuous Release of Economies of Scale, Comprehensive Leap in Operational Efficiency According to International Financial Reporting Standards (IFRS), Seyond’s annual revenue reached approximately...

COVALENT-211 Phase II enrolling insulin-deficient type 2 diabetes patients COVALENT-212 Phase II enrolling type 2 diabetes patients uncontrolled with a GLP-1 receptor agonist-based therapyTopline 26-week primary endpoint data from both Phase II studies anticipated 4Q 2026 SAN CARLOS, Calif., March 31, 2026 (GLOBE NEWSWIRE) — Biomea Fusion, Inc. (“Biomea” or “Biomea Fusion” or “the Company”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity medicines company, today announced that the first patient has been dosed in its newly initiated Phase II programs, COVALENT-211 and COVALENT-212, evaluating icovamenib in patients with type 2 diabetes (“T2D”), marking a key step in advancing icovamenib into Phase II development in targeted patient populations failing standard-of-care therapies as established in the clinical trial COVALENT-111. “These...

Atos Advances AI-Ready Digital Transformation with Lumen Network as a Service Irving, Texas, USA – March 31, 2026 – Atos, a global leader of AI-powered digital transformation today announced a significant advancement in its digital infrastructure strategy through expanded adoption of Lumen’s Network as a Service (NaaS) across its North America data centers, marking a strategic step in its digital transformation journey toward AI-ready, adaptive infrastructure. The initiative delivers greater agility, cost efficiency, and resiliency while enabling seamless connectivity to cloud and edge ecosystems. As enterprises accelerate their digital transformation and adoption of AI, automation, and agentic workflows, network infrastructure must respond in real time. Lumen’s on-demand, consumption-based NaaS provides Atos with a dynamic foundation...